Improved tnf binders

Patent metadata

Field	Value
Publication number	US-2017190769-A1
Application number	US-201715456824-A
Country	US
Kind code	A1
Filing date	Mar 13, 2017
Priority date	Nov 12, 2015
Publication date	Jul 6, 2017
Grant date	—

Abstract

The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.

First claim

1 . An immunoglobulin single variable domain (ISVD) comprising SEQ ID NO: 40.

2 . An immunoglobulin single variable domain (ISVD) consisting of SEQ ID NO: 40.

Assignees

• Ablynx Nv

Inventors

• Buyse Marie-Ange
• Boucneau Joachim
• Casteels Peter
• Van Heeke Gino

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P1/02

  Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title